text
"['\n2. 연결재무제표\n가. 연결재무상태표\n분 기 연 결 재 무 상 태 표\n\xa0제 72 기\xa0\xa0 3분기 : 2020년 09월 30일 현재\n\xa0제 71 기\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 : 2019년 12월 31일 현재\n한화생명보험주식회사와 그 종속기업\n(단위 : 원)\n과\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 목\n주\xa0 석\n제 72(당) 3분기\n제 71(전)기\n자\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 산\n\u3000\nI. 현금및현금성자산\n5,6,7\n1,083,890,637,974\n950,704,341,946\nII. 예치금\n5,6,7\n563,592,079,500\n1,019,690,023,130\nIII. 당기손익인식유가증권\n5,6,8\n7,791,196,703,237\n7,165,143,101,330\nIV. 매도가능유가증권\n5,6,8\n73,759,179,031,889\n70,628,054,197,034\nV. 관계기업 및 공동기업투자\n10\n248,701,083,435\n230,827,515,895\nVI. 대출채권\n5,6,11\n30,002,819,601,366\n28,812,796,035,718\nVII. 유형자산\n13,14\n1,754,253,010,552\n1,855,045,463,942\nVIII. 투자부동산\n13,14\n2,755,735,236,706\n2,553,537,514,521\nIX. 무형자산\n14\n1,143,062,478,701\n1,162,552,077,169\nX. 사용권자산\n14,15\n94,485,836,320\n78,778,708,272\nXI. 파생상품자산\n5,6,12\n199,359,895,838\n297,987,437,629\nXII. 당기법인세자산\n79,557,555,907\n141,448,560,064\nXIII. 이연법인세자산\n18,585,393,790\n15,337,826,588\nXIV. 기타금융자산\n5,6,16\n1,548,063,734,177\n1,761,323,112,500\nXV. 기타자산\n17\n3,075,336,951,836\n3,048,780,748,385\nXVI. 특별계정자산\n20\n23,915,400,939,652\n22,128,080,482,144\n자\xa0 \xa0 \xa0 산\xa0 \xa0 \xa0 총\xa0 \xa0 \xa0 계\n148,033,220,170,880\n141,850,087,146,267\n부\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 채\nI. 보험계약부채\n18\n102,707,032,115,671\n99,268,147,652,861\nII. 계약자지분조정\n19\n1,549,565,695,157\n1,206,758,557,909\nIII. 당기법인세부채\n4,634,858,920\n5,049,254,773\nIV. 이연법인세부채\n1,427,556,933,378\n1,066,199,991,253\nV. 파생상품부채\n5,6,12\n601,709,807,951\n607,563,008,835\nVI. 순확정급여부채\n21\n185,651,192,195\n173,802,168,607\nVII. 충당부채\n22\n17,620,800,702\n16,472,542,187\nVIII. 기타금융부채\n5,6,15,23\n2,274,929,743,512\n2,532,400,592,970\nIX. 기타부채\n24\n260,318,003,939\n154,147,320,075\nX. 특별계정부채\n20\n23,751,803,170,376\n22,826,270,838,863\n부\xa0 \xa0 \xa0 채\xa0 \xa0 \xa0 총\xa0 \xa0 \xa0 계\n132,780,822,321,801\n127,856,811,928,333\n자\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 본\n지배기업의 소유주에게 귀속되는 자본\nI. 자본금\n25\n4,342,650,000,000\n4,342,650,000,000\nII. 기타불입자본\n25\n(457,326,729,307)\n(457,886,936,004)\nIII. 신종자본증권\n26\n2,056,343,999,076\n2,056,297,477,526\nIV. 기타자본구성요소\n27\n3,798,167,285,806\n2,820,597,421,914\nV. 이익잉여금\n28\n4,111,649,634,456\n3,924,201,158,687\n비지배지분\n1,400,913,659,048\n1,307,416,095,811\n자\xa0 \xa0 \xa0\xa0 본\xa0 \xa0 \xa0\xa0 총\xa0 \xa0 \xa0\xa0 계\n\u3000\n15,252,397,849,079\n13,993,275,217,934\n부\xa0 채\xa0 및\xa0 자\xa0 본\xa0 총\xa0 계\n\u3000\n148,033,220,170,880\n141,850,087,146,267\n나. 연결포괄손익계산서\n\xa0분 기 연 결 포 괄 손 익 계 산 서\n제 72 기 3분기 : 2020년 1월 1일부터 2020년 09월 30일까지\n제 71 기 3분기 : 2019년 1월 1일부터 2019년 09월 30일까지\n한화생명보험주식회사와 그 종속기업\n(단위 : 원)\n과\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 목\n주 석\n제 72(당) 3분기\n제 71(전) 3분기\n3 개 월\n\xa0누\xa0\xa0 적\n3 개 월\n누\xa0\xa0 적\nI. 영업수익\n5,650,789,046,203\n19,331,079,455,497\n6,814,018,865,503\n19,445,302,740,309\n\xa0 1. 보험료수익\n30\n4,088,595,948,102\n12,190,870,345,906\n3,885,559,424,292\n11,623,004,707,889\n\xa0 2. 재보험수익\n31\n221,546,840,757\n936,143,973,286\n367,198,654,566\n1,050,686,170,717\n\xa0 3. 이자수익\n29,40\n819,787,301,649\n2,311,641,792,852\n754,514,808,482\n2,237,215,515,872\n\xa0 4. 구상이익\n(188,441,880)\n292,652,399\n1,137,819,723\n3,577,959,156\n\xa0 5. 당기손익인식유가증권 평가 및 처분이익\n29\n64,578,417,609\n135,467,648,202\n38,648,343,959\n131,474,061,743\n\xa0 6. 매도가능유가증권 평가 및 처분이익\n29\n198,187,543,827\n847,531,528,850\n80,212,551,011\n280,544,418,091\n\xa0 7. 외환거래이익\n29\n(359,567,507,580)\n1,012,424,944,699\n1,018,875,681,037\n2,188,519,088,193\n\xa0 8. 파생상품평가 및 거래이익\n12,29\n127,654,036,994\n423,873,033,967\n195,347,697,840\n416,232,687,218\n\xa0 9. 기타수익\n32\n224,525,457,130\n601,990,955,578\n165,138,016,563\n607,600,331,240\n\xa0 10. 특별계정수입수수료\n229,859,778,076\n736,968,302,485\n249,904,057,192\n725,712,010,512\n\xa0 11. 특별계정수익\n20\n35,809,671,519\n133,874,277,273\n57,481,810,838\n180,735,789,678\nII. 영업비용\n5,443,882,521,411\n18,901,412,482,191\n6,725,826,190,840\n19,263,055,914,137\n\xa0 1. 보험계약부채전입액\n18\n1,162,538,766,411\n3,448,342,816,625\n1,078,812,386,273\n3,234,996,586,582\n\xa0 2. 지급보험금\n33,40\n2,984,901,988,160\n9,214,417,896,582\n2,991,792,751,579\n8,756,233,650,857\n\xa0 3. 재보험비용\n31\n255,569,191,655\n1,002,983,892,095\n377,169,735,626\n1,141,455,936,040\n\xa0 4. 사업비\n34,40\n489,057,065,456\n1,504,203,433,515\n492,695,537,360\n1,480,707,662,446\n\xa0 5. 신계약비상각비\n17\n308,388,812,613\n929,444,622,593\n287,536,692,785\n933,216,949,743\n\xa0 6. 재산관리비\n35,40\n23,400,146,896\n95,000,153,622\n22,728,805,209\n95,917,090,654\n\xa0 7. 손해조사비\n36\n31,223,768,162\n87,666,034,396\n28,877,601,004\n84,302,961,452\n\xa0 8. 당기손익인식유가증권 평가 및 처분손실\n29\n(29,518,441,999)\n82,816,294,873\n8,762,009,138\n41,367,833,200\n\xa0 9. 매도가능유가증권 평가 및 처분손실\n29\n122,730,351,325\n320,773,579,130\n60,703,129,776\n344,800,644,794\n\xa0 10. 대출채권및수취채권 평가 및 처분손실\n29\n9,068,442,753\n75,013,284,527\n45,958,157,308\n104,582,232,380\n\xa0 11. 외환거래손실\n29\n55,182,922,274\n244,707,220,307\n4,777,902,955\n120,271,176,446\n\xa0 12. 파생상품평가 및 거래손실\n12,29\n(196,508,903,942)\n1,325,151,388,536\n1,154,944,356,724\n2,389,384,575,126\n\xa0 13. 기타비용\n37\n180,218,528,299\n395,984,696,107\n106,447,664,506\n338,367,200,041\n\xa0 14. 특별계정지급수수료\n11,820,211,829\n41,032,892,010\n5,615,541,542\n16,715,624,698\n\xa0 15. 특별계정비용\n20\n35,809,671,519\n133,874,277,273\n59,003,919,055\n180,735,789,678\nIII. 영업이익\n206,906,524,792\n429,666,973,306\n88,192,674,663\n182,246,826,172\nIV. 영업외수익\n38\n11,806,994,785\n24,944,036,399\n13,559,373,913\n52,199,149,967\nV. 영업외비용\n38\n12,844,512,153\n30,584,238,441\n10,952,632,422\n42,729,619,492\nVI. 법인세비용차감전순이익\n205,869,007,424\n424,026,771,264\n90,799,416,154\n191,716,356,647\nVII. 법인세비용\n39\n56,988,823,788\n112,420,492,224\n17,838,173,930\n30,033,142,305\nVIII. 분기순이익\n148,880,183,636\n311,606,279,040\n72,961,242,224\n161,683,214,342\nIX. 법인세비용차감후 기타포괄손익\n152,297,635,174\n1,051,765,026,555\n252,160,541,630\n1,084,762,057,978\n\xa0 1. 당기손익으로 재분류되지 않는 포괄손익\n460,865,316\n2,386,745,757\n433,239,493\n3,191,132,349\n\xa0\xa0 1) 유형자산재평가이익\n460,865,316\n2,480,995,310\n433,239,493\n3,191,132,349\n\xa0\xa0 2) 순확정급여부채의 재측정요소\n-\n(94,249,553)\n-\n-\n\xa0 2. 후속적으로 당기손익으로 재분류될 수 \xa0 \xa0 \xa0 있는\xa0포괄손익\n151,836,769,858\n1,049,378,280,798\n251,727,302,137\n1,081,570,925,629\n\xa0\xa0 1) 매도가능금융자산평가손익\n181,311,402,006\n1,057,176,840,708\n226,617,833,029\n1,122,711,537,306\n\xa0\xa0 2) 만기보유금융자산평가손익\n-\n-\n(17,152,155,537)\n(78,726,088,082)\n\xa0\xa0 3) 관계기업의 기타포괄손익지분\n178,329,135\n2,829,434,495\n3,430,057\n(948,428,807)\n\xa0\xa0 4) 위험회피목적파생상품평가손익\n(18,998,257,077)\n(41,522,825,851)\n(2,700,259,096)\n(123,296,502,757)\n\xa0\xa0 5) 특별계정기타포괄손익\n7,848,815,260\n33,222,652,615\n11,146,511,940\n83,884,265,035\n\xa0\xa0 6) 해외사업장환산외환차이\n(18,503,519,466)\n(2,327,821,169)\n33,811,941,744\n77,946,142,934\nX. 분기총포괄손익\n301,177,818,810\n1,363,371,305,595\n325,121,783,854\n1,246,445,272,320\nXI. 분기순손익의 귀속\n148,880,183,636\n311,606,279,040\n72,961,242,224\n161,683,214,342\n\xa0 1. 지배기업의 소유주\n125,444,240,537\n283,944,924,047\n65,963,330,732\n156,085,340,722\n\xa0 2. 비지배지분\n23,435,943,099\n27,661,354,993\n6,997,911,492\n5,597,873,620\nXII. 분기총포괄손익의 귀속\n301,177,818,810\n1,363,371,305,595\n325,121,783,854\n1,246,445,272,320\n\xa0 1. 지배기업의 소유주\n264,165,156,784\n1,261,520,410,097\n298,300,003,806\n1,153,543,972,531\n\xa0 2. 비지배지분\n37,012,662,026\n101,850,895,498\n26,821,780,048\n92,901,299,789\nXIII. 주당이익\n\xa0\xa01. 기본 및 희석주당이익\n135\n279\n55\n124\n다. 연결자본변동표\n분 기 연 결 자 본 변 동 표\n제 72 기 3분기 : 2020년 1월 1일부터 2020년 09월 30일까지\n제 71 기 3분기 : 2019년 1월 1일부터 2019년 09월 30일까지\n한화생명보험주식회사와 그 종속기업\n(단위 : 원)\n과\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 목\n자\xa0 본\xa0 금\n기타불입자본\n신종자본증권\n기타자본구성요소\n이익잉여금\n지배기업의소유주 귀속\n비지배지분\n총\xa0 \xa0 계\n2019.1.1 (전기초)\n4,342,650,000,000\n(458,006,536,981)\n1,558,000,197,526\n878,705,504,134\n3,985,549,304,135\n10,306,898,468,814\n1,122,758,599,561\n11,429,657,068,375\nI. 분기총포괄손익\n\xa0 1. 분기순이익\n-\n-\n-\n-\n156,085,340,722\n156,085,340,722\n5,597,873,620\n161,683,214,342\n\xa0 2. 유형자산재평가이익\n-\n-\n-\n3,191,132,349\n-\n3,191,132,349\n-\n3,191,132,349\n\xa0 3. 매도가능금융자산평가손익\n-\n-\n-\n1,041,574,350,358\n-\n1,041,574,350,358\n81,137,186,948\n1,122,711,537,306\n\xa0 4. 만기보유금융자산평가손익\n-\n-\n-\n(88,788,548,464)\n-\n(88,788,548,464)\n10,062,460,382\n(78,726,088,082)\n\xa0 5. 관계기업의 기타포괄손익지분\n-\n-\n-\n(470,083,036)\n-\n(470,083,036)\n(478,345,771)\n(948,428,807)\n\xa0 6. 위험회피목적파생상품평가손익\n-\n-\n-\n(119,819,339,361)\n-\n(119,819,339,361)\n(3,477,163,396)\n(123,296,502,757)\n\xa0 7. 특별계정기타포괄손익\n-\n-\n-\n83,881,231,159\n-\n83,881,231,159\n3,033,876\n83,884,265,035\n\xa0 8. 해외사업환산손익\n-\n-\n-\n77,889,888,804\n-\n77,889,888,804\n56,254,130\n77,946,142,934\nII. 자본에 직접 인식된 주주와의 거래\n\xa0 1. 연차배당\n-\n-\n-\n-\n(75,139,025,000)\n(75,139,025,000)\n(7,381,629,970)\n(82,520,654,970)\n\xa0 2. 신종자본증권 발행\n-\n-\n498,297,280,000\n-\n-\n498,297,280,000\n-\n498,297,280,000\n\xa0 3. 신종자본증권 배당\n-\n-\n-\n-\n(63,097,252,068)\n(63,097,252,068)\n(9,240,000,000)\n(72,337,252,068)\nⅢ. 비지배지분의 증감\n-\n-\n-\n-\n-\n-\n29,918,455,547\n29,918,455,547\n2019.9.30 (전분기말)\n4,342,650,000,000\n(458,006,536,981)\n2,056,297,477,526\n1,876,164,135,943\n4,003,398,367,787\n11,820,503,444,275\n1,228,956,724,927\n13,049,460,169,202\n2020.1.1 (당기초)\n4,342,650,000,000\n(457,886,936,004)\n2,056,297,477,526\n2,820,597,421,914\n3,924,201,158,687\n12,685,859,122,123\n1,307,416,095,811\n13,993,275,217,934\nI. 분기총포괄손익\n\xa0 1. 분기순이익\n-\n-\n-\n-\n283,944,924,047\n283,944,924,047\n27,661,354,993\n311,606,279,040\n\xa0 2. 재평가잉여금의대체\n-\n-\n-\n(5,622,158)\n5,622,158\n-\n-\n-\n\xa0 3. 유형자산재평가손익\n-\n-\n-\n2,480,995,310\n-\n2,480,995,310\n-\n2,480,995,310\xa0\n\xa0 4. 순확정급여부채의 재측정요소\n-\n-\n-\n(94,249,553)\n-\n(94,249,553)\n-\n(94,249,553)\n\xa0 5. 매도가능금융자산평가손익\n-\n-\n-\n984,830,235,220\n-\n984,830,235,220\n72,346,605,488\n1,057,176,840,708\xa0\n\xa0 6. 관계기업의 기타포괄손익지분\n-\n-\n3,383,750,375\n-\n3,383,750,375\n(554,315,880)\n2,829,434,495\xa0\n\xa0 7. 위험회피목적파생상품평가손익\n-\n-\n-\n(43,957,116,098)\n-\n(43,957,116,098)\n2,434,290,247\n(41,522,825,851)\n\xa0 8. 특별계정기타포괄손익\n-\n-\n-\n33,228,665,156\n-\n33,228,665,156\n(6,012,541)\n33,222,652,615\n\xa0 9. 해외사업환산손익\n-\n-\n-\n(2,296,794,360)\n-\n(2,296,794,360)\n(31,026,809)\n(2,327,821,169)\nII. 자본에 직접 인식된 주주와의 거래\n\xa0 1. 연차배당\n-\n-\n-\n-\n(22,541,707,500)\n(22,541,707,500)\n-\n(22,541,707,500)\n\xa0 2. 신종자본증권 발행\n-\n-\n46,521,550\n-\n-\n46,521,550\n-\n46,521,550\n\xa0 3. 신종자본증권 배당\n-\n-\n-\n-\n(73,960,362,936)\n(73,960,362,936)\n(8,353,333,338)\n(82,313,696,274)\n\xa0 4. 주식기준보상\n-\n560,205,560\n-\n-\n-\n560,205,560\n-\n560,205,560\n\xa0\xa05. 자기주식처분손실\n-\n1,137\n-\n-\n-\n1,137\n1,077\n2,214\n2020.9.30 (당분기말)\n4,342,650,000,000\n(457,326,729,307)\n2,056,343,999,076\n3,798,167,285,806\n4,111,649,634,456\n13,851,484,190,031\n1,400,913,659,048\n15,252,397,849,079\n라. 연결현금흐름표\n분 기 연 결 현 금 흐 름 표\n제 72 기 3분기 : 2020년 1월 1일부터 2020년 09월 30일까지\n제 71 기 3분기 : 2019년 1월 1일부터 2019년 09월 30일까지\n한화생명보험주식회사와 그 종속기업\n(단위 : 원)\n과\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 목\n주 석\n제 72(당) 3분기\n제 71(전) 3분기\nⅠ. 영업활동으로 인한 현금흐름\n\u3000\n1,499,495,718,433\n484,457,706,889\n\xa0 \xa0 1. 분기순이익\n311,606,279,040\n\u3000\n161,683,214,342\n\xa0 \xa0 2. 조정\n42\n1,986,778,267,525\n\u3000\n1,915,927,528,209\n\xa0 \xa0 3. 영업활동으로 인한 자산ㆍ부채의 변동\n42\n(3,411,740,509,585)\n\u3000\n(3,721,047,798,580)\n\xa0 \xa0 4. 이자의 수취\n2,237,930,010,191\n\u3000\n2,121,947,006,256\n\xa0 \xa0 5. 이자의 지급\n(19,478,787,565)\n\u3000\n(20,534,810,488)\n\xa0 \xa0 6. 배당금의 수취\n369,997,756,889\n\u3000\n419,071,880,896\n\xa0 \xa0 7. 법인세환급(부담)액\n24,402,701,938\n\u3000\n(392,589,313,745)\nⅡ. 투자활동으로 인한 현금흐름\n\u3000\n(1,296,785,485,871)\n(1,916,123,330,972)\n\xa0 \xa0 1. 매도가능금융자산의 처분\n11,998,361,012,277\n\u3000\n7,001,139,118,091\n\xa0 \xa0 2. 만기보유금융자산의 상환\n-\n\u3000\n65,330,887,429\n\xa0 \xa0 3. 투자부동산 및 유형자산의 처분\n4,048,641,246\n\u3000\n101,100,267,846\n\xa0 \xa0 4. 무형자산의 처분\n8,324,574,659\n\u3000\n-\n\xa0 \xa0 5. 관계기업투자의 처분\n6,057,000,000\n\u3000\n2,495,068,150\n\xa0 \xa0 6. 관계기업투자의 배당\n7,047,894,439\n\u3000\n9,496,776,322\n\xa0 \xa0 7. 예치보증금의 감소\n21,835,458,244\n\u3000\n54,125,833,378\n\xa0 \xa0 8. 비지배지분의 증가\n-\n33,400,000,000\n\xa0 \xa0 9. 연결범위변동으로 인한 현금흐름\n(19,806,970,526)\n4,735,023,045\n\xa0 \xa0 10. 매도가능금융자산의 취득\n(12,403,253,635,313)\n(7,705,975,268,753)\n\xa0 \xa0 11. 만기보유금융자산의 취득\n-\n(613,150,132,693)\n\xa0 \xa0 12. 위험회피목적 파생상품의 정산\n(767,745,923,173)\n(584,778,513,699)\n\xa0 \xa0 13. 투자부동산 및 유형자산의 취득\n(48,441,500,857)\n(85,243,580,612)\n\xa0 \xa0 14. 관계기업투자의 취득\n(26,616,442,784)\n(55,905,614,007)\n\xa0 \xa0 15. 무형자산의 취득\n(68,643,854,220)\n(46,083,639,491)\n\xa0 \xa0 16. 예치보증금의 증가\n(7,951,739,863)\n(53,774,555,978)\n\xa0 \xa0 17. 선급금의 증가\n-\n(43,035,000,000)\nⅢ. 재무활동으로 인한 현금흐름\n(66,373,221,550)\n279,430,944,260\n\xa0 \xa0 1. 비지배지분의 감소\n(8,353,333,338)\n(16,621,629,970)\n\xa0 \xa0 2. 임대보증금 증가\n11,174,386,681\n9,632,261,556\n\xa0 \xa0 3. 임대보증금 감소\n(8,099,029,988)\n(11,636,679,724)\n\xa0 \xa0 4. 신종자본증권 발행\n46,521,550\n498,297,280,000\n\xa0 \xa0 5. 신종자본증권 배당\n(64,568,050,000)\n(43,904,350,000)\n\xa0 \xa0 6. 배당금의 지급\n(22,541,707,500)\n(75,139,025,000)\n\xa0 \xa0 7. 자기주식의 처분\n2,215\n-\n\xa0 \xa0 8. 차입금의 감소\n(53,354,143,000)\n(135,100,000,000)\n\xa0 \xa0 9. 차입금의 증가\n52,759,307,367\n-\n\xa0 \xa0 10. 기타금융부채의 변동\n66,360,548,624\n92,151,188,971\n\xa0 \xa0 11. 리스부채의 감소\n(39,797,724,161)\n(38,248,101,573)\nⅣ. 현금및현금성자산의 순증가(감소)(Ⅰ+Ⅱ+Ⅲ)\n136,337,011,012\n(1,152,234,679,823)\nⅤ. 기초 현금및현금성자산\n950,704,341,946\n1,838,709,692,131\nⅥ. 외화표시 현금및현금성자산 환율변동효과\n(3,150,714,984)\n8,958,511,852\nⅦ. 분기말 현금및현금성자산\n1,083,890,637,974\n695,433,524,160\n']"
